111 related articles for article (PubMed ID: 29045782)
1. Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
Tejeda EJC; Bello AM; Wasilewski E; Koebel A; Dunn S; Kotra LP
J Med Chem; 2017 Nov; 60(21):8876-8887. PubMed ID: 29045782
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.
Sarswat A; Wasilewski E; Chakka SK; Bello AM; Caprariello AV; Muthuramu CM; Stys PK; Dunn SE; Kotra LP
Bioorg Med Chem; 2017 May; 25(9):2643-2656. PubMed ID: 28341402
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.
Wei L; Wasilewski E; Chakka SK; Bello AM; Moscarello MA; Kotra LP
J Med Chem; 2013 Feb; 56(4):1715-22. PubMed ID: 23421315
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.
Moscarello MA; Lei H; Mastronardi FG; Winer S; Tsui H; Li Z; Ackerley C; Zhang L; Raijmakers R; Wood DD
Dis Model Mech; 2013 Mar; 6(2):467-78. PubMed ID: 23118341
[TBL] [Abstract][Full Text] [Related]
5. Photochemical Control of Protein Arginine Deiminase (PAD) Activity.
Mondal S; Parelkar SS; Nagar M; Thompson PR
ACS Chem Biol; 2018 Apr; 13(4):1057-1065. PubMed ID: 29517899
[TBL] [Abstract][Full Text] [Related]
6. Peptidyl Arginine Deiminases and Neurodegenerative Diseases.
Tu R; Grover HM; Kotra LP
Curr Med Chem; 2016; 23(2):104-14. PubMed ID: 26577926
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly sensitive fluorescence probe for peptidyl arginine deiminase (PAD) activity.
Kunieda K; Kawaguchi M; Ieda N; Nakagawa H
Bioorg Med Chem Lett; 2019 Apr; 29(7):923-928. PubMed ID: 30773431
[TBL] [Abstract][Full Text] [Related]
8. Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Muth A; Subramanian V; Beaumont E; Nagar M; Kerry P; McEwan P; Srinath H; Clancy K; Parelkar S; Thompson PR
J Med Chem; 2017 Apr; 60(7):3198-3211. PubMed ID: 28328217
[TBL] [Abstract][Full Text] [Related]
9. Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis.
De Keyser J; Schaaf M; Teelken A
Neurosci Lett; 1999 Jan; 260(1):74-6. PubMed ID: 10027703
[TBL] [Abstract][Full Text] [Related]
10. Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?
Lange S; Gallagher M; Kholia S; Kosgodage US; Hristova M; Hardy J; Inal JM
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587234
[TBL] [Abstract][Full Text] [Related]
11. Targeting PADI2 could stop the progression of myeloma.
Tanday S
Lancet Oncol; 2016 Aug; 17(8):e325. PubMed ID: 27425813
[No Abstract] [Full Text] [Related]
12. Induction of peptidylarginine deiminase 2 and 3 by dibutyryl cAMP via cAMP-PKA signaling in human astrocytoma U-251MG cells.
Masutomi H; Kawashima S; Kondo Y; Uchida Y; Jang B; Choi EK; Kim YS; Shimokado K; Ishigami A
J Neurosci Res; 2017 Jul; 95(7):1503-1512. PubMed ID: 27704563
[TBL] [Abstract][Full Text] [Related]
13. Novel furan-containing peptide-based inhibitors of protein arginine deiminase type IV (PAD4).
Teo CY; Tejo BA; Leow ATC; Salleh AB; Abdul Rahman MB
Chem Biol Drug Des; 2017 Dec; 90(6):1134-1146. PubMed ID: 28581157
[TBL] [Abstract][Full Text] [Related]
14. Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.
Watzlawik JO; Kahoud RJ; Ng S; Painter MM; Papke LM; Zoecklein L; Wootla B; Warrington AE; Carey WA; Rodriguez M
J Neurochem; 2015 Sep; 134(5):865-78. PubMed ID: 25866077
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. GnRH Stimulates Peptidylarginine Deiminase Catalyzed Histone Citrullination in Gonadotrope Cells.
Khan SA; Edwards BS; Muth A; Thompson PR; Cherrington BD; Navratil AM
Mol Endocrinol; 2016 Oct; 30(10):1081-1091. PubMed ID: 27603413
[TBL] [Abstract][Full Text] [Related]
17. The Development of Benzimidazole-Based Clickable Probes for the Efficient Labeling of Cellular Protein Arginine Deiminases (PADs).
Nemmara VV; Subramanian V; Muth A; Mondal S; Salinger AJ; Maurais AJ; Tilvawala R; Weerapana E; Thompson PR
ACS Chem Biol; 2018 Mar; 13(3):712-722. PubMed ID: 29341591
[TBL] [Abstract][Full Text] [Related]
18. Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration.
Horibata S; Rogers KE; Sadegh D; Anguish LJ; McElwee JL; Shah P; Thompson PR; Coonrod SA
BMC Cancer; 2017 May; 17(1):378. PubMed ID: 28549415
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel PAD4 inhibitors based on a pharmacophore model derived from transition state coordinates.
Wei Y; Liu R; Liu C; Jin J; Li D; Lin J
J Mol Graph Model; 2017 Mar; 72():88-95. PubMed ID: 28064083
[TBL] [Abstract][Full Text] [Related]
20. Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.
Bello AM; Wasilewski E; Wei L; Moscarello MA; Kotra LP
ACS Med Chem Lett; 2013 Feb; 4(2):249-53. PubMed ID: 24900657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
